Cannabinoid Clinical Trials: Cannabis Effects on Alcohol Urge

Clinical Takeaway

Cannabis affects alcohol cravings differently depending on a person’s working memory capacity, meaning that cognitive factors help explain why some people experience increased or decreased urge to drink after using cannabis. In a controlled clinical trial, individuals with higher working memory capacity responded differently to cannabis than those with lower capacity when exposed to alcohol cues. Clinicians should recognize that cognitive profile may influence how cannabis use interacts with alcohol craving in patients with heavy drinking patterns.

#15 Working memory capacity predicts cannabis-induced effects on alcohol urge.

Citation: Gunn Rachel L et al.. Working memory capacity predicts cannabis-induced effects on alcohol urge.. Addictive behaviors. 2026. PMID: 41275744.

Study type: Journal Article, Randomized Controlled Trial  |  Topic area: Geriatrics  |  CED Score: 11

Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2

Why This Matters
Understanding how working memory capacity predicts differential cannabis effects on alcohol urge has significant clinical implications for personalizing substance use interventions and predicting which patients may benefit from cannabis-based treatments for alcohol dependence. This research identifies a measurable cognitive biomarker that could enable clinicians to stratify patients and anticipate adverse effects, such as increased alcohol cravings in those with lower working memory capacity. By establishing individual differences as moderators of cannabis efficacy, this study moves toward precision medicine approaches that could improve treatment outcomes and reduce harm in dual alcohol and cannabis use populations.

Quality Gate Alerts:

  • Preclinical only

Abstract: BACKGROUND: Cannabis has shown mixed results in its association with alcohol urge, which may be explained by individual differences. One such factor, working memory capacity (WMC) is associated with drug-related cue reactivity and implicated in alcohol use and problems. In the current study, we examined whether WMC moderates the acute effect of cannabis on alcohol urge in a randomized placebo-controlled crossover trial. METHODS: Participants aged 21 to 44 (N = 125, 32 % female) reporting heavy alcohol use and cannabis use ≥ twice weekly completed a laboratory protocol across three days where they smoked a placebo, 3.1 % delta-9 tetrahydrocannabinol (THC), and 7.2 % THC cannabis cigarette. Participants were asked to rate their alcohol urge pre and post smoking. Prior to the experimental sessions, participants completed WMC measures including the n-back and the complex span tasks, operation span (OS) and symmetry span (SS). RESULTS: Those with higher WMC, as assessed via the SS task, reported significantly lower alcohol urge after smoking the 7.2 %, but not the 3.1 %, THC dose, relative to placebo. Performance on the OS task was not associated with alcohol urge. Lower WMC as determined via n-back scores was associated with higher alcohol urge overall, but n-back scores did not moderate the impact of cannabis on alcohol urge. CONCLUSION: Findings suggest individuals with higher but not lower working memory experience lower alcohol urge under acute effects of cannabis. Although cannabis is increasingly perceived as a substitute for alcohol, individuals with lower working memory may be less likely to experience such benefits when attempting to reduce their drinking.

Clinical Perspective

🧠 This crossover trial offers an intriguing mechanistic hypothesis that working memory capacity may predict individual variation in how cannabis affects alcohol craving, potentially explaining why prior studies show mixed results in this population. The study’s randomized placebo-controlled design strengthens causal inference, though the relatively small sample size, restriction to ages 21 to 44, and potential selection bias toward individuals willing to use both substances limit generalizability to broader clinical populations. Several important confounders remain uncontrolled for in the abstract, including cannabis dose and route of administration, baseline alcohol use severity, concurrent medications, and whether participants were actively seeking alcohol use treatment versus using recreationally. From a clinical standpoint, if replicated in larger and more diverse samples, this work could support more personalized counseling around cannabis use in patients with alcohol use disorder, potentially cautioning those with lower working memory capacity about heightened craving vulnerability, though we would need substantially more evidence before recommending cannabis as any form of alcohol harm reduction strategy.

Full Article  |  PubMed